Link Matthew 4

What Happened

• Matthew Link, a director of FibroBiologics, was granted 30,803 derivative securities (reported as acquired) on 2026-06-23. The reported price is $0.00, so the aggregated acquisition value is $0. This transaction is reported as an award/grant (Form 4 code "A").

Key Details

• Transaction date: 2026-06-23; Report filed: 2026-06-23.
• Amount: 30,803 derivative shares/options; price reported: $0.00; total reported value: $0.
• Shares owned after the transaction: not specified in the information provided.
• Footnote: The award will vest in full upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting (per footnote F1).
• Timeliness: Filing shows the same report and filing date (no late filing indicated from provided data).

Context

• This is a director compensation grant (derivative award), not an open‑market purchase or sale. Derivative awards typically represent stock options or restricted-equity units that convert to stock upon vesting or exercise; the filing’s footnote specifies vesting conditions.
• Such grants are common for board members as part of compensation and do not by themselves signal immediate buying or selling of shares.